BCS set out to design and build high-performance cyclotrons, establishing expertise in cyclotrons ranging from 1 MeV to 70 MeV and beyond. Its vision was to advance global healthcare by delivering ...
Cyclotrons have fundamentally transformed nuclear medicine and cancer therapy over the past decade, with major milestones ...
Cyclotrons have fundamentally transformed nuclear medicine and cancer therapy over the past decade, with major milestones ...
Co-locating Convergent's manufacturing at NorthStar establishes an integrated and reliable supply chain for CONV01-<ALPHA> drug product production with Ac-225, relieving supply constraints for ...
New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...
A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...
A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved tisotumab vedotin (Genmab AS) for adults with recurrent or metastatic cervical cancer. The decision, made via the ...
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial ( NCT05720130) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback